Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?-Reference-Cited by-同舟云学术

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Published:2010-11 Issue: Volume:36 Page:S56-S61
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Rizzo Sergio,Bronte Giuseppe,Fanale Daniele,Corsini Lidia,Silvestris Nicola,Santini Daniele,Gulotta Gaspare,Bazan Viviana,Gebbia Nicola,Fulfaro Fabio,Russo Antonio

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference54 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

2. Regional liver therapy using oncolytic virus to target hepatic colorectal metastases;Carpenter;Semin Oncol,2010

3. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway;Russo;Oncology,2009

4. Genetic alterations during colorectal-tumor development;Vogelstein;N Engl J Med,1988

5. Oncogene addiction;Weinstein;Cancer Res,2008

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come;Journal of Surgical Oncology;2024-08-19

2. KRAS silencing alters chromatin physical organization and transcriptional activity in colorectal cancer cells;2024-04-16

3. KRAS silencing impacts chromatin organization and transcriptional activity in colorectal cancer cells;2024-02-14

4. KRAS inhibition impacts chromatin organization and transcriptional performance in colorectal cancer cells;2023-12-19

5. The clinicopathological significance and potential function of ULK1 in colon cancer;Biotechnology and Genetic Engineering Reviews;2023-05-16